



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3 rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)
Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181

January 31, 2023

The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051. Code: JAGSNPHARM	The Manager Listing Agreement The BSE Limited Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001. SCRIP Code: 507789
--	---

Sub: Intimation of Board Meeting

Dear Sir/Ma'am,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that a Meeting of Board of Directors of the Company will be held on Wednesday, February 8, 2023, inter alia, to consider and approve the Standalone Unaudited Financial Results of the Company for the quarter ended December 31, 2022.

As per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company was closed on January 1, 2023 and will remain closed until February 10, 2023.

This is for your information purposes.

For JAGSONPAL PHARMACEUTICALS LIMITED

SALAPAKA
VENKATA
SUBHA RAO

Digitally signed by SALAPAKA
VENKATA SUBHA RAO
DN: cn=SALAPAKA VENKATA SUBHA
RAO c=IN o=Personal
Reason: I am the author of this document
Location:
Date: 2023-01-31 15:25+05:30

S.V. SUBHA RAO
Compliance Officer and C F O